GEJ Adenocarcinoma Treatment Based on ESOPEC Study | Daniel Catenacci, MD | ASCO22 GI Cancer Updates скачать в хорошем качестве

GEJ Adenocarcinoma Treatment Based on ESOPEC Study | Daniel Catenacci, MD | ASCO22 GI Cancer Updates

Dr. Daniel Catenacci, gastrointestinal cancer care expert, reviews the following case question, incorporating updates from the 2022 ASCO annual conference that have changed the standard of care. 65 year old man diagnosed with poorly differentiated GEJ adenocarcinoma (Seiwert Type II) and staged clinically with EUS, CT, diagnostic laparoscopy, and PET as cT3N1Mx. What is your preferred treatment approach: A. Perioperative ECF (3 cycles before and 3 cycles after surgery) B. Neoadjuvant chemoRT (Carbo/Taxol) C. Neoadjuvant chemoRT (Carbo/Taxol) then adjuvant nivolumab for eligible patients D. Perioperative FLOT (4 cycles before and 4 cycles after surgery) Answers and Rationales: A. Perioperative ECF (3 cycles before and 3 cycles after surgery): This is not correct because the FLOT4 study demonstrated Superiority of FLOT over MAGIC (ECF) clearly. B. Neoadjuvant chemoRT (Carbo/Taxol) This is not entirely correct given the CM577 results demonstrating benefit of adjuvant Nivolumab for eligible patients. C. Neoadjuvant chemoRT (Carbo/Taxol) then adjuvant nivolumab for eligible patients This is a correct answer based on the CM577 study. D. Perioperative FLOT (4 cycles before and 4 cycles after surgery). This is a correct answer based on the FLOT4 study. Currently both answers C and D are correct. The ESOPEC study will compare FLOT vs CROSS, which may shed light on the better. Backbone upon which to add immunotherapy. Other studies are assessing various IO treatments with FLOT or CROSS backbones. Find more oncology education opportunities at www.totalhealthconferencing.com